The trajectory of the erectile dysfunction drug presents a complex picture for investors. While the initial release generated significant gains, the lapse of its patent opened the avenue to off-brand alternatives, https://sachinkgsr499765.blogchaat.com/42099346/sildenafil-and-big-pharma-a-risky-investment